|1.||Daniell, Henry: 2 articles (10/2015 - 01/2011)|
|2.||Steinstraesser, Lars: 2 articles (01/2012 - 01/2003)|
|3.||Steinstraesser, L: 2 articles (03/2007 - 07/2001)|
|4.||Subramanian, Hariharan: 1 article (10/2015)|
|5.||Gupta, Kshitij: 1 article (10/2015)|
|6.||Kotian, Akhil: 1 article (10/2015)|
|7.||Ali, Hydar: 1 article (10/2015)|
|8.||Schäfer-Korting, Monika: 1 article (05/2014)|
|9.||Grohmann, Lisa: 1 article (05/2014)|
|10.||Korting, Hans Christian: 1 article (05/2014)|
07/01/2001 - "The objective of this study was to examine the efficacy of protegrin-1 in killing multiple drug-resistant microbes isolated from human burn patients. "
07/01/2001 - "For thein vitroexperiment, bilayer radial diffusion was performed comparing standard antibiotics with protegrin-1 on multiple-drug-resistant microbial organisms isolated from infected burn wounds. "
01/01/2007 - "Protegrin-1 (PG-1) is known as a potent antibiotic peptide; it prevents infection via an attack on the membrane surface of invading microorganisms. "
10/06/2015 - "Preclinical evaluation of Retrocyclins (RC-100, RC-101) and Protegrin-1 (PG-1) antimicrobial peptides (AMPs) is important because of their therapeutic potential against bacterial, fungal and viral infections. "
01/01/2011 - "Retrocyclin-101 (RC101) and Protegrin-1 (PG1) are two important antimicrobial peptides that can be used as therapeutic agents against bacterial and/or viral infections, especially those caused by the HIV-1 or sexually transmitted bacteria. "
01/01/2012 - "Cell proliferation of the fibrosarcoma cell line, HT1080, and human fibroblasts was determined in vitro after treatment with [D]-K(6)L(9), [D]-K(3)H(3)L(9), and Protegrin-1. "
01/01/2012 - "Our aim was to assess the toxic efficacy of [D]-K(6)L(9), [D]-K(3)H(3)L(9), and Protegrin-1 against the fibrosarcoma cell line, HT1080, and primary human fibroblasts to analyze the potential of these peptides as therapeutic options against STSs. "
|4.||Wound Infection (Wound Infections)
07/01/2001 - "This study shows that protegrin-1 potentially may be used as an alternative or adjunct therapy to standard agents used to treat wound infections."
03/01/2007 - "After wound infection had been established (4 days after inoculation), each wound chamber was topically treated with P-novispirin G10, protegrin-1 or carrier control. "
|5.||Dengue (Dengue Fever)
01/01/2012 - "In this study, the antiviral activity of protegrin-1 (PG-1, RGGRLCYCRRRFCVCVGR) peptide towards dengue NS2B-NS3pro and viral replication in Rhesus monkey kidney (MK2) cells was investigated. "
01/01/2012 - "Protegrin-1 inhibits dengue NS2B-NS3 serine protease and viral replication in MK2 cells."
|2.||Serine Proteases (Serine Protease)
|5.||Anti-Bacterial Agents (Antibiotics)